Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?

Florian Huemer Simon Peter Gampenrieder Alexander Schlattau Richard Greil

Clin Breast Cancer

Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, Salzburg, Austria. Electronic address:

Published: February 2014

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.clbc.2013.09.009	DOI Listing

Publication Analysis

Top Keywords

overcoming resistance

resistance her2-targeting

her2-targeting agents

agents fifth-line

fifth-line therapy

therapy place

place bevacizumab

bevacizumab her2+

her2+ breast

breast cancer?

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!